The findings from the above studies indicate that the plasma apoM levels may be reduced in patients with MODY3 than in controls and patients with T1D; however, plasma apoM levels are not useful for distinguishing patients with MODY3 from those with T2D. This evidence concerns the gene APOM and type 2 diabetes mellitus.